Literature DB >> 9629704

[Toxic epidermal necrolysis after the use of intermediate dose of cytosine arabinoside].

M S Figueiredo1, M Yamamoto, J Kerbauy.   

Abstract

UNLABELLED: Toxic epidermal necrolysis is a drug-induced dermatologic disease related to Lyell syndrome, erythema multiforme and Stevens-Johnson syndrome.
PURPOSE: To report a fatal case of toxic epidermal necrolysis owing to intermediate dose of cytarabine. CASE REPORT: A 16 year-old female patient with acute lymphocytic leukemia (LLA-L1) treated with the Protocol of the Brazilian Group for Treatment of Leukemia of Childwood (GBTLI-85-AR). On the second day after the administration of intermediate dose of cytarabine (1.5 g/m2 i.v. every 12 hours for 3 days), she presented bullous lesions in the left buttock that disseminated envolving to necrosis, sepsis, and death on the 13th day.
CONCLUSION: Cytarabine is frequently associated with dermatologic toxicity but, until now, there is no other case of toxic epidermal necrolysis described.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9629704     DOI: 10.1590/s0104-42301998000100011

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.209


  3 in total

1.  Life-threatening dermatologic adverse events in oncology.

Authors:  Alyx C Rosen; Yevgeniy Balagula; Dennis W Raisch; Vishvas Garg; Beatrice Nardone; Nicole Larsen; Jennifer Sorrell; Dennis P West; Milan J Anadkat; Mario E Lacouture
Journal:  Anticancer Drugs       Date:  2014-02       Impact factor: 2.248

2.  Auricular oedema and dyshidrotic eczema in a patient with acute myeloid leukaemia treated with cytarabine.

Authors:  K Brandt; K Schäkel; F Stölzel; J Janschek; G Ehninger; M Schaich
Journal:  Case Rep Oncol       Date:  2010-10-04

Review 3.  Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.

Authors:  Chau Yee Ng; Chun-Bing Chen; Ming-Ying Wu; Jennifer Wu; Chih-Hsun Yang; Rosaline Chung-Yee Hui; Ya-Ching Chang; Chun-Wei Lu
Journal:  J Immunol Res       Date:  2018-01-17       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.